Levosimendan metabolites OR-1855 and OR-1896 were eliminated slowly, with the active metabolite OR-1896 having a mean half-life of 81 hours regardless of the 7-day infusion dose (P=0.992).
Absolute Event Rate: 81% vs 81%
p-value: p=0.992
AIMS: The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in patients with congestive heart failure. METHODS: Levosimendan was administered as a continuous intravenous infusion for 7 days. Twelve subjects received the drug at an infusion rate of 0.05 micro g kg(-1) min(-1) and 12 at a rate 0.1 micro g kg(-1) min(-1). RESULTS: Steady state concentrations of levosimendan were achieved within 4 h. Peak concentrations of the metabolites occurred after termination of the infusion. The mean (+/- SD) half-life of the active metabolite OR-1896 was 81 +/- 37 h after the lower dose and 81 +/- 28 h after the higher dose (P = 0.992, 95% confidence interval on the difference -27.5, 27.7). CONCLUSIONS: The metabolites of levosimendan, OR-1855 and OR-1896, were formed and eliminated slowly, their peak concentrations occurring after termination of the 7-day infusion of the drug.
Antila et al. (Tue,) conducted a other in congestive heart failure (n=24). Levosimendan vs. 0.1 micro g kg(-1) min(-1) dose group (compared to 0.05 dose group) was evaluated on Half-life of the active metabolite OR-1896 (95% CI -27.5, 27.7, p=0.992). Levosimendan metabolites OR-1855 and OR-1896 were eliminated slowly, with the active metabolite OR-1896 having a mean half-life of 81 hours regardless of the 7-day infusion dose (P=0.992).